March 13, 2024 News by Andrea Lobo, PhD Phase 1 trial of KYV-101 opening in progressive MS without relapses Researchers at Stanford University have partnered with Kyverna Therapeutics to conduct an investigator-initiated clinical trial of the company’s cell-based therapy, KYV-101, in people with progressive forms of multiple sclerosis (MS) without relapses. The open-label Phase 1 trial (NCT06138132) will take place at the Stanford Multiple Sclerosis…
November 30, 2023 News by Marisa Wexler, MS Stem cell therapy well tolerated in SPMS clinical trial A novel therapy in which neural stem cells are injected into the brain was well tolerated by 15 people with secondary progressive multiple sclerosis (SPMS) in a pilot clinical trial. Participants’ disability levels and cognition, as well as markers of inflammation and nerve damage, all remained stable for up…
August 22, 2023 News by Patricia Inacio, PhD Progressive MS trial of vidofludimus calciumĀ fully enrolled A global Phase 2 clinical trial investigating theĀ oral therapy vidofludimus calcium (IMU-838) in people with progressive forms of multiple sclerosis (MS) has reached full enrollment, the treatment’s developer, Immunic Therapeutics, reports. Called CALLIPER (NCT05054140), the trial is assessing whether the neuroprotective effects of vidofludimus calciumĀ seen in…
June 8, 2023 News by Lindsey Shapiro, PhD Microglial activation reduced in 5 of 6 SPMS patients on nasal foralumab Reductions in microglial activation have been observed in the brains of five of six patients with nonactive secondary progressive multiple sclerosis (SPMS) who received treatment with Tiziana Life Science’s foralumab nasal spray. Microglia, resident immune cells in the brain, are believed to play a role in driving inflammation…
March 27, 2023 News by Marisa Wexler, MS More, earlier damage seen in primary progressive MS vs SPMS People with primary progressive multiple sclerosis (MS) may experience more severe inflammatory activity and nerve damage early on in the course of their disease as compared with individuals who have secondary progressive MS, a new study indicates. The results also suggest that primary progressive MS patients tend to have…
September 16, 2022 Columns by John Connor All Quiet on the MS Front ā Well, Nearly Note: The second half of this column details digestive symptoms that may make readers uncomfortable.Ā In the five years that Iāve written this “irreverent journey with multiple sclerosis (MS),” quoting from my very own bio at the foot of this column, I think Iāve only covered this “quiet”…
August 23, 2022 News by Marisa Wexler, MS Global Prevalence of SPMS Estimated, But Seen to Vary Widely Worldwide, about 22 in every 100,000 people live with secondary progressive multiple sclerosis (SPMS), a review study analyzing data across various countries reported. Its researchers found substantial variability in SPMS rates country-by-country, with countries closer to the poles generally reporting higher prevalence than those near the equator. Rates also…
August 19, 2022 Columns by John Connor MS and Sex: Everything You Wanted to Know but Were Never Told to Ask Now, I know the phrase “Iām going to do my own research” has become a catch-all for conspiracy theorists who are out to prove spurious nonsense, merely by finding even more spurious websites they can whirl down like Alice falling through that there looking glass. Proper research costs serious money…
July 18, 2022 News by Margarida Maia, PhD Case Suggests Soliris as Potential Treatment for Progressive MS Note: This story was updated July 20, 2022, to correct the headline to reflect that Soliris might be a potential treatment for progressive MS based on data from a single case report. A female patient with undiagnosed secondary progressive multiple sclerosis (SPMS) was placed on Soliris (eculizumab)…
July 14, 2022 News by Marisa Wexler, MS EMBOLD Study of ATA188 in Progressive MS Is Given Go-ahead An independent committee of experts has recommended that the Phase 2 portion of the EMBOLD clinical trial continue as planned without a sample size adjustment, following an analysis of safety and effectiveness data. The trial is testing Atara Biotherapeutics‘ experimental medication ATA188 in progressive forms of multiple…
June 20, 2022 Columns by Ed Tobias MS News That Caught My Eye Last Week: Vidofludimus Calcium, Foralumab, Exoskeleton, Dysport Vidofludimus Calcium Safely Reduced RRMS Brain Lesions Vidofludimus calcium, also called IMU-838, is an oral therapy designed to reduce the activity of B- and T-cells. These are immune cells believed to be responsible for the inflammation that results in MS damage. In this small study, active lesions ā including…
April 12, 2022 News by Marta Figueiredo, PhD 8 More SPMS Patients Cleared for Foralumab Nasal Spray Treatment Based on findings from the first two secondary progressive multiple sclerosis (SPMS) patients givenĀ foralumab nasal spray, an experimental therapy, the U.S. Food and Drug Administration (FDA) has approved starting treatment in up to eight other patients under a special access program. Those enrolled in this intermediate-size expanded access…
March 4, 2022 Columns by John Connor The Captain and His No. 2 There I was, swinging away in my hoist at 9 p.m., though my swinging London of the 2020s wasn’t only 60 years later, it was also a lot, lot grimmer. My carer and maybe still wife, Jane, stood below in a controlled fury. If nothing else, she might…
March 4, 2022 News by Marta Figueiredo, PhD Masitinib Slows Disability Progression in PPMS, Non-active SPMS Masitinib, AB Scienceās experimental oral therapy, significantly slows disability progression in adults with primary progressive multiple sclerosis (PPMS) and non-active secondary progressive MS (SPMS), according to final data from the AB07002 Phase 2b/3 clinical trial. These findings, indicating that the trial met its main goal, support…
February 4, 2022 Columns by John Connor At 64, I’m Surprised to Be Scrambling to Mount a Chariot As usual, Iāve gone for what I hope to be an intriguing headline, because youāve got to grab a reader by any means necessary. If youāve read this far, Iām winning! This saga goes back well over a year, when my neurologist suggested I participate in a clinical trial for…
January 5, 2022 News by Marta Figueiredo, PhD AB Science OK’d to Start Masitinib Phase 3 Trial for Progressive MS The French Health Authority has approved AB Scienceās request to launch a Phase 3 clinical trial to confirm the safety and effectiveness of its lead candidate masitinib in adults with primary progressive multiple sclerosis (PPMS) and nonactive secondary progressive MS (SPMS). āWe are very excited to initiate…
November 4, 2021 Columns by Jennifer (Jenn) Powell When Loss Is Expected, How Do We Cope? It is hard to watch the decline in real time. It happens before my very eyes. Like “Groundhog Day,” I wake, I try, and I do. I persevere because that is who I am. I push past the chaos in my body. I don’t see every new pain as…
October 19, 2021 News by Marta Figueiredo, PhD #ECTRIMS2021 ā Spinal Cord Lesions Predictive of SPMS Conversion in CIS Editorās note: TheĀ Multiple Sclerosis News Today team is providing in-depth coverage of the virtual 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Oct. 13ā15. GoĀ hereĀ to see the latest stories from the conference. Lesions…
October 15, 2021 News by Marta Figueiredo, PhD #ECTRIMS2021 ā Stem Cell Transplant May Better Treat SPMS Than DMTs Editorās note: TheĀ Multiple Sclerosis News Today team is providing in-depth coverage of the virtual 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Oct. 13ā15. GoĀ here to see the latest stories from the conference.
August 19, 2021 News by Marta Figueiredo, PhD MediciNova Planning Phase 3 Trial of Oral Ibudilast for SPMS MediciNovaĀ is planning to launch a Phase 3 clinical trial that will evaluate its investigational oral candidate ibudilast (MN-166) in people with secondary progressive multiple sclerosis (SPMS) without relapses. The company is actively engaging with potential partners that could help fund the study. āOver the past quarter, we…
October 15, 2020 News by Forest Ray PhD Mayzent Approved for Active Secondary Progressive MS in Scotland The Scottish Medicines Consortium (SMC) has approved Mayzent (siponimod) for the treatment of active secondary progressive multiple sclerosis (SPMS) in Scotland. Mayzent, developed by Novartis, is a tablet taken once daily to counter a person’s disability progression. SPMS gradually develops from relapsing-remitting MS, and is…
July 7, 2020 News by Marta Figueiredo, PhD Study: Mavenclad Shows Long-term Effectiveness at Preventing MS Relapses, Disease Progression MavencladĀ (cladribine) prevents relapses and disease progression in more than half of patients with relapsing forms of multiple sclerosis (MS) for at least five years after the last dose, according to a real-life study from Italy. These findings, based on real-world data from Italian MS patients previously treated…
August 15, 2018 News by Patricia Inacio, PhD Long-term DMT Use Seen to Lower Likelihood of RRMS Progressing to SPMS in Study Long-term treatment with disease-modifying therapies (DMTs) appears to lessen the risk of disease worsening inĀ relapsing-remitting multiple sclerosis (RRMS) patients, an 18-year follow-up study suggests. But these therapies were not seen to benefit those who had progressed to secondary progressive multiple sclerosis (SPMS). The study, āOnset of secondary…
May 21, 2018 News by Iqra Mumal, MSc Fat-Derived Stem Cells a Potential Safe, Feasible Treatment for Secondary Progressive MS, Trial Shows Fat-derived stem cells are a safe and feasible treatment strategy for patients with secondary progressive multiple sclerosis, results from a Phase 1/2 clinical trial show. Findings were published in the study, āAdipose-derived mesenchymal stem cells (AdMSC) for the treatment of secondary-progressive multiple sclerosis: A triple blinded,…
January 3, 2018 Columns by Mike Knight Turning Corners with MS: Ocrevus, Biotin, and 2018 Like a lot of people with MS, I took part in the āGreat Ocrevus Rush of 2017,ā with the fanfare surrounding the release of the first therapy in the United States known to have some ability to stem the advancement of primary and secondary progressive MS.
May 30, 2017 News by Patricia Silva, PhD #CMSC17 – Review Suggests Certain MS Patient Groups May Discontinue Disease-Modifying Treatments Older patients with secondary progressive multiple sclerosis (SPMS) as well as older relapsing patients whose MS has been inactive after five years may safely discontinue their treatments, Canadian researchers at Vancouver’sĀ University of British ColumbiaĀ argue. TheirĀ Sanofi Genzyme-sponsoredĀ study, āWhen Should Disease-Modifying Treatments Be Discontinued in Patients with Multiple Sclerosis: An…
May 16, 2016 News by Margarida Azevedo, MSc Mitoxantrone, a Drug for Progressive and Severe Relapsing MS, Linked to Colorectal Cancer Risk Mitoxantrone, Ā a multiple sclerosis (MS) Ā drug that isĀ alreadyĀ associated with a higher risk for leukemia and heart damage, may also raise a person’s risk ofĀ colorectal cancer, researchers at theĀ University of WĆ¼rzburg, in Germany, reported. If confirmed in larger studies, the findings indicate that colonoscopies should be conducted on MS patients after…
January 19, 2016 News by admin Anti-LINGO-1: All You Need to Know Recently, Biogen released results from its Phase 2 acute optic neuritis (AON) RENEW trial which tested Anti-LINGO-1. Learn more about this results here. So what isĀ Anti-LINGO-1? According to the MS Society,Ā Anti-LINGO-1 (also known as BIIB033) is a treatment in development by the pharmaceutical company Biogen which is currently…
July 24, 2015 News by Maureen Newman Masitinib Shows Promise in Study For Treating Progressive MS Patients Progressive multiple sclerosis patients treated with AB Science’s lead compound AB07002 (masitinib) in a Phase 3 clinical trial showed positive results in a non futility test (a test to determine if an experimental therapy shows some sign of efficacy). With the successful completion of the futility analysis, AB Science is…
April 15, 2015 News by Patricia Silva, PhD Beta-Interferon Therapy Has No Effect on Secondary Progressive MS Onset According to Study A team led by researchers at the University of British ColumbiaĀ in Canada recently published results in the European Journal of NeurologyĀ showing thatĀ treatment with beta-interferon has no effect on secondary progressive multiple sclerosis (MS) disease onset. The study is entitled āBeta-interferon exposure and…